Pharma BD Deal Intelligence
A $0.4B bolt-on protein-engineering platform quietly became the R&D engine behind Taltz, a $3.2B/year blockbuster — one of Lilly's best-aged small deals.
Full analysis, sources & comparables →Lilly to acquire AME at $18/share in cash, stock, or combination; AMEsystem directed-evolution platform positioned as core to Lilly's biotechnology product…
Top 6 monoclonal antibodies grew at ~20% CAGR from 2004-2013, validating Lilly's 2003 strategic move to acquire antibody optimization capability via AME.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Announced November 21, 2003. $18/share = ~$400M. Antibody optimization platform (AMEsystem). Closed February 2004. Sources: SEC 425, Lilly investor PR, Pharmaletter.
A $0.4B bolt-on protein-engineering platform quietly became the R&D engine behind Taltz, a $3.2B/year blockbuster — one of Lilly's best-aged small deals.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Applied Molecular Evolution Inc. (this deal) | 2003 | $400M | 88 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
| Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. | 2026 | $1.3B | 65 |